EGFR and non-small cell lung carcinoma: The National Drug Reimbursement List (NDRL) has four first-line EGFR TKIs (i.e., gefitinib, erlotinib, icotinib, and afatinib) currently registered to treat patients with EGFR-mutation-positive NSCLC dating back to 2016.